European venture capitalists are no longer prepared to take any risk with their investments, undermining the biotech sector. That, anyway, is the opinion of many a frustrated biotech entrepreneur.
Who should profit from cutting-edge academic research: the scientists or the institution that funds them? Both, in a new biotech company launched by one of Sweden’s leading researchers.
European companies are set to increase their investment in R&D by 5 per cent per annum over the next three years, closing the gap with US counterparts.
Receive the Funding Newswire [full access requires a subscription] each Tuesday, our Policy Bulletin each Thursday, and news about bridging Europe’s east-west innovation gap twice a month in The Widening.
A unique international forum for public research organisations and companies to connect their external engagement with strategic interests around their R&D system.